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V. T. H. B. M Smit12 and R. A. Nout1 for the PORTEC Study Group
BACKGROUND: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing
pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with the
results of pathology review and molecular analysis.
METHODS: 427 women with HIR endometrial cancer were randomised between 2002–2006 to VBT or EBRT. Primary endpoint was
vaginal recurrence (VR). Pathology review was done in 97.4%, combined with molecular analysis.
RESULTS: Median follow-up was 116 months; 10-year VR was 3.4% versus 2.4% for VBT vs. EBRT (p= 0.55). Ten-year pelvic
recurrence (PR) was more frequent in the VBT group (6.3% vs. 0.9%, p= 0.004), mostly combined with distant metastases (DM). Ten-
year isolated PR was 2.5% vs. 0.5%, p= 0.10, and DM 10.4 vs. 8.9% (p= 0.45). Overall survival for VBT vs. EBRT was 69.5% vs. 67.6%
at 10 years (p= 0.72). L1CAM and p53-mutant expression and substantial lymph-vascular space invasion were risk factors for PR and
DM. EBRT reduced PR in cases with these risk factors.
CONCLUSION: Long-term results of the PORTEC-2 trial conﬁrm VBT as standard adjuvant treatment for HIR endometrial cancer.
Molecular risk assessment has the potential to guide adjuvant therapy. EBRT provided better pelvic control in patients with
unfavourable risk factors.
British Journal of Cancer (2018) 119:1067–1074; https://doi.org/10.1038/s41416-018-0310-8
INTRODUCTION
Women with endometrial cancer (EC) are often diagnosed at early
stage of disease, and in general have a favourable prognosis1.
Randomised trials have shown that adjuvant radiation therapy (RT)
for stage I EC signiﬁcantly reduced the risk of locoregional
recurrence, without difference in overall survival2–5. High-
intermediate risk (HIR) factors were deﬁned in both the PORTEC-
1 and GOG#99 trials to identify women who were at relatively
higher risk of recurrence2,4. As the majority of recurrences in these
trials were located in the vaginal vault, the Post-Operative
Radiation Therapy in Endometrial Cancer trial (PORTEC)-2 trial
was initiated in 2002 to investigate the efﬁcacy of vaginal
brachytherapy (VBT) as compared to pelvic RT (EBRT) for women
with stage I EC with HIR factors to maximise local control, with
reduced toxicity and better quality of life. Five-year results of the
PORTEC-2 trial showed equally low rates of vaginal recurrence in
both treatment arms, without differences in overall and disease-
free survival6. Higher rates of treatment-related toxicity, especially
gastro-intestinal symptoms with impact on health-related quality
of life (HRQL), were recorded in the EBRT arm, while patients who
received VBT reported HRQL and symptoms scores which did not
differ from those of an age-matched norm population7–9. As a
result, VBT became standard adjuvant treatment for women with
HIR endometrial carcinoma.
More recently, novel molecular risk factors in endometrial
cancer were described. In 2013 the Cancer Genome Atlas (TCGA)
group published results of an extensive genomic characterisation
of endometrial cancer, deﬁning four different molecular sub-
groups with distinct prognosis: a POLE-ultramutated group; a
microsatellite-unstable hypermutated group; a copy-number-low
group and a copy-number-high group driven by TP53 mutation10.
POLE-ultramutated EC had very favourable outcomes, while those
with TP53 mutation had an unfavourable prognosis. For the copy-
number-low group, no speciﬁc driver mutation was identiﬁed.
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Analysis of these four molecular subgroups by their surrogate
markers (p53 expression by immunohistochemistry; PCR based
determination of microsatellite instability (MSI); and analysis of
POLE exonuclease domain mutations by Sanger sequencing) in
more than 900 parafﬁn-embedded (FFPE) tissue samples of the
PORTEC-1 and PORTEC-2 biobank, led to a useful and practical
molecular classiﬁcation tool for the clinic. Results of these analyses
conﬁrmed the prognostic signiﬁcance of these 4 molecular
subgroups, which was conﬁrmed in a similar analysis reported
by Talhouk et al.11,12. Moreover, several other strong clinicopatho-
logic and molecular risk factors such as substantial (diffuse or
multifocal) lymph-vascular space invasion (LVSI), L1CAM expres-
sion and beta catenin mutation were analysed. A molecular
integrated risk proﬁle was deﬁned which was able to distinguish
favourable, intermediate and unfavourable subgroups within the
group of HIR EC, with a clear difference in outcomes11–14.
With current knowledge of molecular risk features, the question
remains whether patient selection for vaginal brachytherapy can
be further improved, thereby decreasing both over- and under-
treatment. It was hypothesised that a small subgroup of patients
with unfavourable risk features such as TP53 mutation, L1CAM
expression ( > 10%), or substantial LVSI might have had better
pelvic control if they had received EBRT. The present analysis was
done to analyse long-term outcomes of the PORTEC-2 trial, and
evaluate whether speciﬁc clinicopathologic and molecular risk
factors can be used to determine optimal adjuvant treatment for
subgroups at higher risk of recurrence.
MATERIAL AND METHODS
Patient selection and eligibility criteria
The PORTEC-2 trial was a multicentre randomised trial, which
recruited patients between May 2002 and September 2006.
Women were eligible if they had been diagnosed with endome-
trial carcinoma with high-intermediate risk factors (HIR) and were
randomly allocated to either vaginal brachytherapy (VBT) or pelvic
radiotherapy (EBRT). HIR was deﬁned as either (1) FIGO 1988 stage
1C (≥50% myometrial invasion) with age greater than 60 and
grade 1 or 2; or (2) FIGO 1988 stage 1B (<50% myometrial
invasion) with age greater than 60 and grade 3; or (3) FIGO
1988 stage 2A (endocervical glandular involvement, which is stage
I in FIGO 2009) with any age, except for grade 3 with deep
invasion. Exclusion criteria were: serous or clear cell carcinoma;
staging lymphadenectomy; > 8 weeks interval between surgery
and radiotherapy; history of previous malignancy; previous
radiotherapy, hormonal or chemotherapy; Crohn’s disease or
ulcerative colitis. Detailed information on patient selection,
randomisation and masking, treatment and follow-up was
described previously6. The primary endpoint of the study was
vaginal recurrence (VR). Secondary endpoints were pelvic
recurrence (PR), distant recurrence (DR), overall survival, endome-
trial cancer-related survival (CSS), disease-free survival (DFS), and
toxicity and quality of life. The trial protocol was approved by the
Dutch Cancer Society (CKTO 2001–04) and the Ethics Committees
of participating centres. Written informed consent was given by all
patients.
Treatment and follow-up
Radiation therapy was administered within 8 weeks after total
abdominal hysterectomy and bilateral salpingo-oophorectomy.
Lymphadenectomy was not performed routinely15,16. In case of
suspicious lymph nodes found at surgery, these were selectively
removed. EBRT was delivered to the pelvic area using a total dose
of 46 Gy in 2 Gy daily fractions, ﬁve times per week. The clinical
target volume consisted of the proximal vagina, parametria, and
internal, external and caudal common iliac lymph node regions up
to the level of the promontory. Treatment planning was
performed by CT-based three-dimensional conformal planning
using multiple ﬁelds with individual shielding; usually a 4-ﬁeld box
technique.
VBT was delivered with a vaginal cylinder to the proximal half of
the vagina, with dose speciﬁcation at 5 mm distance from the
surface of the cylinder. High-dose rate (HDR) equipment was used
in 85%, delivering a dose of 21 Gy in 3 fractions of 7 Gy, with an
interval of 1 week; 15% received an equivalent dose using LDR
(0.5-0.7 Gy/hr) or MDR (1 Gy/hr) equipment6.
Follow-up consisted of alternating visits to the patient’s
gynaecologist and radiation oncologist every 3–4 months in the
ﬁrst 3 years, at 6 month intervals in the 4th and 5th years, and
yearly thereafter, up to at least 7 years. If needed, follow-up
information was obtained from the GP and the national
population registry at 10 years after treatment. At follow-up visits,
physical examination was performed and side-effects or recur-
rence of disease were reported and treated. Patient-reported
health-related quality of life and symptoms were recorded by the
EORTC QLQ-C30 and speciﬁc symptom modules for bladder,
bowel and sexual symptoms. Short-term and long-term quality of
life outcomes have been reported separately7–9.
Pathology review and analysis of molecular characteristics
Central pathology review was performed by specialised gynaeco-
pathologists, after the patient had been included in the trial. More
recently, comprehensive analysis of molecular alterations has
been done, in a translational research project using the pooled
PORTEC-1 and PORTEC-2 biobank11. TCGA molecular subgroups
were assessed using surrogate markers on FFPE tissue sam-
ples11,12. Immunohistochemical techniques and DNA analysis were
used to assess polymerase-epsilon (POLE) mutations; microsatellite
instability (MSI); and p53 protein expression (scored as p53-
wildtype/mutant/null staining)11. In addition, analysis of L1CAM
expression, with > 10% expression being L1CAM positive, and the
presence and quantiﬁcation of LVSI were assessed, according to
the methods described previously13,14. Based on previous
analyses, only substantial LVSI was taken into account, since mild
(focal) LVSI was not associated with increased risk of recurrence14.
Statistical analysis
All randomised patients were kept in the analyses for primary and
secondary endpoints, which was by intention to treat. Analysis of
molecular risk factors was performed only in those patients whose
high-intermediate risk features were conﬁrmed at central pathol-
ogy review (conﬁrmed-HIR). For these analyses of conﬁrmed-HIR
cases, data of the previous study on the molecular risk factors
within the PORTEC-1 and 2 biobank were used (selecting the
PORTEC-2 cases only)11.
Time-to event analyses were done with log-rank tests and Cox
proportional hazards regression models with date of randomisa-
tion as starting point. Both log-rank tests and Cox regression
models were stratiﬁed for FIGO stage but were essentially the
same with and without adjustment, and results are presented
without adjustment. Overall survival (OS) was calculated from date
of randomisation to death from any cause, with censoring at date
of last information for patients alive. Endometrial cancer-related
survival (CSS) was calculated from date of randomisation to date
of death related to endometrial cancer, with censoring of patients
who died of other causes and of patients alive at date of last
follow-up or last information, respectively. Disease-free survival
(DFS) was calculated from date of randomisation to date of
disease recurrence or to date of death from any cause, with
censoring of patients alive and recurrence-free. Data for patients
who were alive and recurrence-free were censored at date of last
follow-up or of information on vital status. The competing risk
method (with death as competing risk) was used for analysis of
vaginal, and pelvic recurrence and distant metastasis. First failure
type was vaginal recurrence when an isolated vaginal recurrence
had occurred; pelvic recurrence in case of pelvic recurrence with
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or without vaginal recurrence; and ﬁrst failure type was distant if a
distant recurrence was diagnosed, with or without pelvic or
vaginal recurrence. The Kaplan-Meier method was used for OS,
CSS and DFS. Analyses of (molecular) risk factors were done using
univariable Cox proportional hazard models11. Risk factors with a
p-value below 0.1 in univariable analysis were included in
multivariable analysis. Chi-square and Fisher’s exact tests were
used to compare (molecular) risk factors between treatment
groups. SPSS was used to perform statistical analyses, version 23.0
(IBM SPSS, Inc., Chicago, IL).
RESULTS
In total, 427 women with HIR endometrial carcinoma were
included in the trial; 214 were randomly assigned to receive EBRT
and 213 to VBT (Fig. 1). Patient and tumour characteristics were
equally distributed over the two treatment groups (Table 1). The
database was frozen on May 1st 2016 and by then, the median
follow-up was 116 months (range 18–163 months).
Long-term results of the intention to treat analysis are
presented in Table 2 and Fig. 2. A total of 12 women developed
a vaginal recurrence, seven in the VBT group and ﬁve in the EBRT
group. The 10-year vaginal recurrence rates were 3.4% and 2.4%
for VBT and EBRT, respectively (p= 0.55). Pelvic recurrences were
diagnosed in 13 women in the VBT group and two in the EBRT
group, with 10-year rates of 6.3% vs. 0.9% (p= 0.004); of these,
2.5% vs. 0.5% were isolated pelvic recurrences (p= 0.10). Ten-year
rates of distant metastases were 10.4% vs. 8.9% for VBT vs EBRT (p
= 0.45). No signiﬁcant differences in ﬁrst failure types were found,
except for simultaneous distant and pelvic recurrence: 3.6% in the
VBT group versus 0.5% in the EBRT group, p= 0.03. Long-term
results of the conﬁrmed-HIR population are shown in the
Supplementary Data Table 2. In this population the 10-year
vaginal recurrence rates were 2.7% vs. 3.1% (p= 0.78) and the
pelvic recurrence rates 7.4% and 1.2% (p= 0.01) for VBT vs. EBRT,
respectively.
A total of 136 women died during follow-up: 70 in the VBT
group and 66 in the EBRT group. Cause of death was endometrial
carcinoma in 30.1%; secondary cancer in 13.2%; and intercurrent
disease in 50.7%. Ten-year overall survival was 69.5% vs. 67.6%
(p= 0.72) and 10-year endometrial cancer-related survival 88.2%
vs. 90.9% (p= 0.42) for VBT vs. EBRT groups, respectively.
Prognostic factors
Central pathology review was available for 416 patients (97.4%).
HIR status was conﬁrmed by the review gynaeco-pathologist in
344 cases (82.7%), while 34 were determined high risk (8.2%) and
38 low risk (9.1%), see Table 1 and Fig. 1. Figure 3a shows the CSS
for the four molecular subgroups in conﬁrmed HIR patients. For
women with tumours harbouring a POLE mutation, 10-year CSS
was 100%, in contrast to 96.2% for no speciﬁc molecular proﬁle,
84.8% for MSI and 62.3% for p53-mutant tumours (p < 0.001).
Among conﬁrmed HIR patients a subgroup of 50 women
presented with any of the unfavourable risk features substantial
LVSI, p53-mutant and/or L1CAM expression; 17.2% in the VBT
group and 12% in the EBRT group, p= 0.18. L1CAM expression
was found in 14 VBT patients, vs. four in the EBRT arm (p= 0.010).
Rates of substantial LVSI and p53-mutant expression did not differ
signiﬁcantly between the treatment arms, see Table 1. Eleven
patients had both p53–mutant and L1CAM expression, and three
had both LVSI and L1CAM expression.
Multivariable analysis of unfavourable risk factors in conﬁrmed
HIR patients is presented in Table 3 and similar results were found
in all patients with material available (Supplementary Data
Table 2). Substantial LVSI was found to be a very strong
independent risk factor for pelvic and distant recurrence (hazard
ratios 8.73 (p= 0.005) and 5.36 (p= 0.001), respectively) and for
endometrial cancer-related survival (HR 7.16, p < 0.001). L1CAM
Central pathology review of 416 patients (97.4%) was assessed:
38 (9.1%) low risk
34 (8.2%) high-risk
344 (82.7%) high-intermediate risk (HIR)
175 patients included in analysis of risk 
factors 
169 patients included in analysis of risk 
factors 
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427 patients randomly assigned
214 allocated to EBRT
207 received EBRT
7 did not receive EBRT
- 5 VBT (patient refusal)
- 1 no radiotherapy (not eligible: low risk)
- 1 EBRT + VBT (not eligible: high risk)
213 allocated to VBT
209 received VBT
4 did not receive VBT
- 2 no radiotherapy (not eligible: low risk)
- 1 EBRT (VBT not feasible)
- 1 died before start of VBT
214 included in intention-to-treat analysis 213 included in intention-to-treat analysis
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175 confirmed-HIR patients in EBRT group 169 confirmed-HIR patients in VBT group 
Fig. 1 Consort diagram of the PORTEC-2 trial with pathology review
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expression (HR 4.18, p= 0.016) and p53-mutant expression (HR
3.35, p= 0.015) were signiﬁcant prognostic factors for distant
recurrence and CSS (HR 5.05, p= 0.006 and HR 3.30, p= 0.015).
Main ﬁndings of multivariable analysis for DFS were similar to
those of CSS (data not shown). Although signiﬁcant in univariable
analysis, L1CAM and p53-mutant expression did not reach
signiﬁcance for pelvic recurrence in multivariable analysis.
Figure 3b and Supplementary Data Fig. 1 show that the higher
risk of total pelvic recurrence in the VBT group is restricted to
patients with unfavourable features.
DISCUSSION
The present analysis of long-term results of the PORTEC-2 trial
conﬁrmed the excellent vaginal control with adjuvant vaginal
brachytherapy for women with high-intermediate risk endometrial
cancer, with 10-year vaginal control above 96% in both arms.
Although the risk of pelvic recurrence was signiﬁcantly (6% vs. 1%)
higher in the VBT group, the majority of these women presented
with simultaneous distant metastasis, resulting in similarly low
rates of isolated pelvic recurrence in both treatment arms.
Moreover, no differences were found in 10-year rates of distant
metastasis and overall survival. As previously reported, low toxicity
rates and better health-related quality of life were found among
women who received VBT compared to EBRT, even after more
than 7 years9. Similar ﬁndings were reported in a Swedish trial
comparing EBRT combined with VBT versus VBT alone for women
with intermediate-risk endometrial cancer17. The 5-year locore-
gional relapse rates were 1.5% vs. 5% (p= 0.013), with crude rates
of vaginal recurrence of 1.9% vs. 2.7%, and quality of life results
favoured VBT. These long-term ﬁndings conﬁrm VBT as the
adjuvant treatment of choice for women with early stage
endometrial cancer with high-intermediate risk features.
Implementation of HIR risk factors as determined in both the
PORTEC-1 and GOG#99 trials for the indication for adjuvant
radiotherapy reduced the number of women who received
radiotherapy by 50% at the time, sparing them unnecessary and
potentially toxic treatment2–4,18. In the PORTEC-1 trial, the 5-year
risk of vaginal recurrence among women with high-intermediate
risk features was reduced from 15% without radiotherapy, to 2%
with EBRT. Although the risk of vaginal recurrence was subse-
quently found in the PORTEC-2 trial to be similarly low with VBT, it
can be argued that this still represents overtreatment, as 8 women
need to be treated to prevent one vaginal recurrence, and
selection for adjuvant treatment could be improved19. Moreover,
EBRT might have provided better pelvic control for the few (6%)
patients who developed pelvic recurrence after VBT, even if the
majority presented with simultaneous distant metastases. These
results indicate there is a clear need for additional risk factors that
improve the current risk classiﬁcation.
Both the TCGA analysis and studies determining the molecular
subgroups by their surrogate markers indicated that distinguish-
ing the four molecular subgroups had strong prognostic
signiﬁcance10–12. Mutation of the tumour suppressor gene TP53
has been related to early tumour progression in multiple cancer
types as well as in endometrial cancer, and is associated with
grade 3 and with non-endometrial (mostly serous) histology, while
POLE mutation leads to only rare recurrence and excellent
outcomes20. MSI is an intermediate risk factor but associated with
Lynch syndrome and might have therapeutic implications. More
recently MSI detection has been replaced by analysis of mismatch
repair deﬁciency (MMRd), and detection of MLH-1 promotor
hypermethylation in those with MMRd21.
Substantial LVSI and L1CAM expression are strong risk factors
for recurrence10,11,13,14. L1CAM is a cell adhesion molecule and
mediates cell motility, is associated with epithelial mesenchymal
transition and early disease spread. Several large series have
conﬁrmed the negative prognostic impact of L1CAM expres-
sion13,22,23. Interestingly, while there is some overlap between
TP53 mutation and L1CAM expression, L1CAM has been shown to
be an independent risk factor, frequently associated with, but
independent from TP53 mutation24. This was conﬁrmed in the
current analysis, where 38% of L1CAM positive patients did not
have p53-mutant expression, and 63% of patients with p53-
mutant expression did not have L1CAM expression. LVSI has long
Table 1. Patient and tumour characteristics and pathology review
Intention to treat population
n= 427 EBRT (n= 214) VBT (n= 213)
Age
</=60 years 8 3.7% 8 3.8%
60-70 years 109 50.9% 99 46.5%
>70 years 97 45.3% 106 49.8%
FIGO 1988 stage
IB 19 8.9% 16 7.5%
IC 172 80.4% 171 80.3%
IIA 23 10.7% 26 12.2%
Myometrial invasion
< 50% 31 14.5% 28 13.1%
> 50% 183 85.5% 185 86.9%
Grade
1 99 46.3% 103 48.4%
2 97 45.3% 94 44.1%
3 18 8.4% 16 7.5%
LVSI
Present 25 11.7% 21 9.9%
Absent 189 88.3% 192 90.1%
Conﬁrmed-HIR at pathology review
n= 344 EBRT (n= 175) VBT (n= 169)
Grade
1 148 84.6% 134 79.3%
2 16 9.1% 23 13.6%
3 11 6.3% 12 7.1%
Substantial LVSI
Yes 9 5.1% 7 4.1%
No 160 91.4% 156 92.3%
Missinga 6 3.4% 6 3.6%
Molecular subgroup
POLE 10 5.7% 6 3.6%
MSI 41 23.4% 36 21.3%
NSMP 103 58.9% 96 56.8%
TP53b 10 5.7% 15 8.9%
Double classiﬁers 4 2.3% 6 3.6%
Missinga 7 4.0% 10 5.9%
L1CAM expressionc
> 10% 4 2.3% 14 8.3%
< 10% 168 96.0% 151 89.3%
Missinga 3 1.7% 4 2.4%
aMaterial not appropriate for test or failed test
bAs assessed by p53 protein expression
cSigniﬁcant difference (p= 0.010)
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been known for its adverse prognostic impact, being associated
with the risk of (microscopic) nodal metastases and with higher
rates of recurrence and lower CSS, both in the presence and
absence of lymph node metastases25,26. A recent large study using
the pooled PORTEC biobank in which LVSI was quantiﬁed and
graded as absent, mild (a single focus or few foci) or substantial
(diffuse or multifocal) showed that substantial LVSI is a highly
signiﬁcant risk factor for pelvic and distant recurrence14.
In this long-term analysis, substantial LVSI, p53-mutant and
L1CAM expression were all strongly associated with the risk of
pelvic recurrence, distant metastasis and endometrial cancer-
related survival. Moreover, in the small subgroup of women with
high-intermediate risk endometrial cancer with any of these
unfavourable risk factors, EBRT provided a signiﬁcantly better
pelvic control than VBT.
Strengths of this study are the uniform and random allocation
of treatment, long and complete follow-up and central pathology
review in 97% of patients. Central pathology review was
performed because various studies had shown frequent inter-
observer variation within the ﬁeld of gynaecopathology, with a
poor reproducibility especially of the intermediate grade27–29.
More recent analysis of the inter-observer variability in the
pathology review of the PORTEC-3 trial, which was required
before randomisation, showed that in 43% of all patients at least
one of the pathology items changed, with grade (20%) and
histological type (15%) being the most frequent items of
disagreement. Upfront pathology review resulted in 8% of all
patients being ineligible for the trial30.
Analysis of the long-term results within the population that was
conﬁrmed-HIR after pathology review in the PORTEC-2 trial ( >
80%) showed no signiﬁcant differences compared to the intention
to treat analysis, possibly also because a similar number of
patients were deemed either low (38) or high risk (34) at
pathology review (Fig. 1, Supplementary Data Table 2).
These long-term results show that among the large group of
women with early stage endometrial cancer with risk features, the
subgroup of patients with unfavourable risk factors is small, and
that the combination of clinicopathologic and molecular factors
adequately select the women who might beneﬁt from EBRT or
more intensive treatment. This is supported by the fact that more
pelvic recurrences occurred in the VBT group, in which more
patients with p53-mutant expression and with L1CAM expression
were found compared to the EBRT group (Table 1).
The potential beneﬁt of adjuvant chemotherapy to decrease
disease recurrence in women with early stage, high-intermediate
or high-risk endometrial cancer has been subject of several trials,
which did not show differences in overall and relapse-free
survival compared to EBRT31,32. In the GOG249 trial, 601 women
with stage I-II endometrial cancer with risk factors (deep invasion,
grade 3 or serous/clear cell histology) were randomised to pelvic
EBRT vs. VBT with three cycles of carboplatin/paclitaxel
chemotherapy. Recently presented 5-year results showed no
differences in relapse- free and overall survival33. However, even
though 89% had lymphadenectomy and were node negative,
pelvic and para-aortic failures were signiﬁcantly more frequent
after VBT and chemotherapy, while acute toxicity was increased,
leading to the conclusion that EBRT remains the standard
adjuvant treatment for early stage, high-risk disease. This ﬁnding
again suggests that results of adjuvant EBRT are similar with and
without lymphadenectomy, as was also seen in the GOG#99 and
PORTEC-1 trial2,4, and that detecting microscopic nodal involve-
ment, similar to extensive LVSI, seems a marker but not a cause of
distant spread. Previous randomised trials have not shown any
survival beneﬁt from lymphadenectomy in early stage dis-
ease15,16. The strength of the molecular markers is that they
may more individually predict if speciﬁc tumours might be at risk
of early disease spread. Therefore, an integrated clinicopathologic
and molecular risk proﬁle has the potential to guide adjuvant
treatment and could distinguish the few women with HIR
endometrial cancer who would beneﬁt from EBRT instead of
standard VBT11,12.
In the currently ongoing PORTEC-4a trial, women with stage I-II
EC with high-intermediate risk features are randomised to receive
adjuvant treatment directed by their integrated molecular risk
proﬁle or standard vaginal brachytherapy34. The molecular proﬁle
stratiﬁes patients into favourable (about 50%) who will be
observed, intermediate risk (about 45%) who will receive
brachytherapy, and an unfavourable group (about 5%) who will
Table 2. Long-term outcomes (intention to treat population)
EBRT (n= 214) VBT (n= 213) HR (95% CI)
Events 5-year % 10-year % Events 5-year % 10-year % VBT:EBRT p value
First failure type
Vaginal recurrence 3 1.1% 1.5% 5 0.9% 3.0% 1.68 (0.40 - 7.03) 0.47
Pelvic recurrence 1 0.5% 0.5% 5 1.4% 2.5% 5.07 (0.59 - 43.41) 0.10
Distant recurrence 18 6.6% 8.9% 22 8.9% 10.4% 1.25 (0.67 - 2.33) 0.49
Distant alone 15 5.7% 7.0% 13 5.5% 6.6% 0.88 (0.42 - 1.86) 0.75
Distant and pelvic 1 0.5% 0.5% 7 3.0% 3.6% 7.16 (0.88 - 58.23) 0.03
Distant and vaginal 2 0.5% 1.1% 1 0.5% 0.5% 0.51 (0.05 - 5.65) 0.58
Total failure
Vaginal recurrence 5 1.9% 2.4% 7 2.4% 3.4% 1.42 (0.45 - 4.46) 0.55
Pelvic recurrence 2 0.9% 0.9% 13 4.6% 6.3% 6.65 (1.50 - 29.48) 0.004
Distant recurrence 18 6.6% 8.9% 22 8.9% 10.4% 1.25 (0.67 - 2.33) 0.49
Endometrial cancer-related
survival
18 93.2% 90.9% 23 91.7% 88.2% 1.29 (0.70 - 2.39) 0.42
Disease-free survival 71 82.1% 68.0% 72 81.2% 66.7% 1.03 (0.74 - 1.43) 0.87
Overall survival 70 84.0% 67.6% 66 84.0% 69.5% 0.94 (0.67 - 1.32) 0.72
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receive EBRT, and thus aims to further reﬁne risk stratiﬁcation,
reduce over- and undertreatment and increase cost-effectiveness.
The PORTEC-4a trial was shown to be feasible by evaluation of the
pilot phase, with a satisfactory patient acceptance rate and
feasibility of performing the molecular assessment within
2 weeks35.
In conclusion, long-term results of PORTEC-2 conﬁrmed VBT as
the adjuvant treatment of choice for women with high-
intermediate risk endometrial cancer. EBRT might provide better
pelvic control in the small subgroup of women with unfavourable
risk factors (substantial LVSI, L1CAM expression or p53-mutant
expression).
Number at risk Number at risk
EBRT 214 196 185 165 141 92 25 EBRT 214 204 187 168 142 92 25
VBT 213 193 176 165 140 102 20 VBT 213 198 182 169 142 103 20
Number at risk Number at risk
EBRT 214 202 185 165 140 92 25 EBRT 214 204 186 168 142 92 25
VBT 213 198 179 166 139 99 19 VBT 213 195 179 166 141 102 20
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Fig. 2 Ten year results of the PORTEC-2 trial
Ten-year results of the PORTEC-2 trial for high-intermediate risk. . .
BG Wortman et al.
1072
ACKNOWLEDGEMENTS
The authors thank all members of the PORTEC study group who contributed to
this study, speciﬁcally the many colleagues and data managers at the
participating centres, who ensured that we had reliable and complete outcome
data even after 10 years of follow-up. Further, we are greatly indebted to the
many women who participated in the PORTEC-2 trial and thank them for sharing
their data and for completing the quality of life questionnaires for so many
years.
a b
Number at risk
0
0.0
0.2
0.4
0.6
0.8
0.0
0.2
0.4
0.6
0.8
1.0 1.0
En
do
m
et
ria
l c
an
ce
r-r
el
at
ed
 s
ur
viv
al
To
ta
l p
el
vic
 re
cu
rre
nc
e
2 4 6
Years  since randomisation
8 10 12 0 2 4 6
Years  since randomisation
8 10 12
POLE 16 16 16 16 14 11 3
NSMP 199 193 184 175 148 98 20
MSI 77 71 64 58 49 31 6
TP53 25 19 14 10 8 6 2
POLE
NSMP
MSI
TP53 p < 0.001
Number at risk
VBT RF + 29 21 16 15 11 8 2
EBRT RF + 21 19 16 13 11 5 1
VB TRF – 140 134 127 121 107 76 16
EBRT RF – 154 147 138 126 106 67 15
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Fig. 3 a Endometrial cancer-related survival by 4 molecular subgroups. b Total pelvic recurrence by unfavourable risk factors (LVSI, p53-
mutant or L1CAM expression)
Table 3. Multivariable analysis of recurrence in conﬁrmed-HIR patients
Pelvic recurrence (total) Distant recurrence Endometrial cancer-related
survival
No. a HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Treatment group
EBRT 163 1 0.054 1 0.805 1 0.740
VBT 154 4.58 (0.97 - 21.52) 0.91 (0.41 - 2.00) 0.87 (0.40 - 1.94)
LVSI
no/mild 301 1 0.005 1 0.001 1 < 0.001
substantial 16 8.73 (1.95 - 39.22) 5.36 (1.91 - 15.07) 7.16 (2.71 - 18.91)
TP53b
wild type 288 1 0.065 1 0.015 1 0.015
mutation 29 3.82 (0.92 - 15.83) 3.35 (1.27 - 8.84) 3.30 (1.26 - 8.64)
L1CAM
< 10% 300 1 0.126 1 0.016 1 0.006
> 10% 17 3.79 (0.69 - 20.93) 4.18 (1.31 - 13.33) 5.05 (1.59 - 16.06)
aTotal no. 317; 27 cases had insufﬁcient material for analysis of all factors
b As assessed by p53 protein expression
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